` HBIO (Harvard Bioscience Inc) vs S&P 500 Comparison - Alpha Spread

HBIO
vs
S&P 500

Over the past 12 months, HBIO has underperformed S&P 500, delivering a return of -86% compared to the S&P 500's +13% growth.

Stocks Performance
HBIO vs S&P 500

Loading
HBIO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
HBIO vs S&P 500

Loading
HBIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
HBIO vs S&P 500

Loading
HBIO
S&P 500
Add Stock

Competitors Performance
Harvard Bioscience Inc vs Peers

S&P 500
HBIO
0KHE
TMO
DHR
207940
Add Stock

Harvard Bioscience Inc
Glance View

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 475 full-time employees. The company went IPO on 2013-10-21. The firm provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The firm organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. The company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The firm's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

HBIO Intrinsic Value
2.3693 USD
Undervaluation 81%
Intrinsic Value
Price
Back to Top